Hexima Limited (ASX:HXL)

Hexima Limited is a clinical stage, anti-infectives focused biotechnology company based in Australia. The company is dedicated to the research and development of plant defensin peptides for applications as human therapeutics. Its lead product candidate, pezadeftide (formally HXP124), is being developed as a potential new prescription treatment for toenail fungal infections (onychomycosis). The company is currently conducting an Australian phase IIb clinical trial to test pezadeftide for this indication.

Hexima Limited holds granted, long-life patents protecting pezadeftide in major markets globally, ensuring its potential commercial value. Founded in 1998, the company has positioned itself as a prominent player in the biotechnology industry.

With its focus on addressing unmet medical needs using innovative solutions, Hexima Limited has garnered the attention of investors. Its last investment of $1.38M came through a Debt Financing in July 2009, with the Government of South Australia as the investor. This not only underscores the financial support behind the company but also highlights its relevance in the biotechnology space.

By targeting a prevalent medical condition with a potentially groundbreaking solution, Hexima Limited demonstrates promise, which could appeal to venture capitalists seeking high-impact investments in the biotech sector.